Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer

Abroad (travel likely)Recruiting

Conditions

Breast Cancer (Early Breast Cancer) · Breast Cancer Survivors · Breast Cancer Prognostic · Early Hormone Receptor-positive (HR-positive) · HER2-negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hôpital Saint-Louis, Paris, France
Contact: Study coordinator (Jacqueline LEHMANN-CHE, MD) · jacqueline.lehmann-che@aphp.fr · 01 56 09 21 11

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year

Cardiovascular Health · Breast Cancer · Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Abroad (travel likely)Recruiting

Toronto, Canada

Clinical Trial Evaluating the Efficacy and Implementation of an Early Adapted Physical Activity to Prevent and Manage Aromatase Inhibitor-induced Musculoskeletal Pain in Breast Cancer (APIS)

Breast Cancer

Abroad (travel likely)Recruiting

Lyon, France · Saint-Priest-en-Jarez, France

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Amiens, France · Angers, France

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Breast Neoplasms · Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Santa Monica, United States · Skokie, United States